Advertisement
09/22/2021

Par intros generic Chantix

Chantix had a market value of approximately $1 billion for the 12 months ended June 30, according to IQVIA.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Par, an Endo company, is introducing the first generic version of Pfizer's Chantix (varenicline tablets), in dosage strengths of 0.5 mg and 1 mg.

Par's varenicline is the first and currently the only available FDA-approved generic version of Chantix in the United States. It is used to help adults stop smoking.

[Read more: Par launches authorized generic of Amitiza]

"This important approval brings the first Chantix generic to the U.S. market," said Jon Holden, senior vice president and general manager, Generics at Endo. "As a reliable, quality supplier, Par is proud to help people during this critical time while also expanding our product portfolio."

[Read more: Rolling with the punches: Generics firms innovate, expand scope to stay competitive

Chantix has a market value of approximately $1 billion for the 12 months ended June 30, according to IQVIA.

    Advertisement
    Advertisement